Benjamin L Maughan

Harvard's 40-year study shows that switching to a healthy diet after diagnosis, rich in olive oil, whole grains, and vegetables, lowers mortality risk by up to 25%. It’s never too late for a new path. 🌿 #LoreleiMucci @HarvardChanSPH @APCCC_Lugano @OncoAlert @ZEROCancer #ProstateCancer #Healthy

💬 Hear Dr. Robert Svatek (@SvatekRob), of @UTHealthSA, break down intradermal #BCG priming from the SWOG S1602 trial, which evaluated BCG strain variation in BCG-naïve #NMIBC: buff.ly/g13Q3xA

Happy birthday, @spsutkaMD! You’re out there breaking barriers and saving lives, and I’m just lucky to know you. Raising a glass (of something green!) to you today!

Progress in rare kidney cancer subtypes depends on collaboration. This month, we’re highlighting the work of the tRCC Project, which is advancing research for translocation renal cell carcinoma (tRCC) by building a comprehensive dataset that combines clinical information, genomic sequencing, and patient-reported experience. For rare cancers like tRCC, every data point matters. Learn more about the project and participation opportunities at trccproject.org #AcceleratingCures #KidneyCancerAwarenessMonth #BetterTogether

Wonderful effort! Please participate. trccproject.org

Prostat Kanseri Sonrası: Nasıl Beslenmeli? Prostat kanseri tanısı sonrası beslenme düzeni, hayatta kalma şansını artırmak için güçlü bir araçtır. Harvard’ın 40 yıllık geniş kapsamlı çalışması, bu yolda bize net bir rehber sunuyor. Prostat Kanseri Sonrası Beslenme: Bilim Ne Diyor? 🧬🍎 📌 Hiçbir zaman geç değil: Tanıdan sonra beslenme düzenini iyileştirmek, genel ölüm riskini %20-25 oranında azaltıyor. 🥗 Akdeniz Diyeti: Zeytinyağı, tam tahıllar, sebze ve baklagil odaklı beslenme en güçlü müttefikiniz. ❤️ Kalbi koru: Erken evre prostat kanserinde en büyük risk kalp hastalıklarıdır. "Kalp dostu" beslenmek, yaşam süresini doğrudan uzatıyor. ✨ Küçük adımlar: Tabağınıza eklediğiniz her renkli sebze, geleceğinize bir yatırımdır. @HarvardChanSPH @harvardmed @KansersizYasam @melikessahin

📢 ONE DAY LEFT to register early for #IKCSEU26 with reduced rates!!! Join us for the leading #kidneycancer meeting, network with colleagues, and enjoy spring in Paris with the KCA! 🔗 bit.ly/4sEB6aL

🧬 Huge kudos to @arcusbio for the commitment to deep translational science while casdatifan is still in an active clinical trial, they are already doing the hard work of building a biomarker framework to understand HIF-2α biology and who benefits most 🔬 This is what dedication to patients looks like. Not waiting until the trial is over to ask the hard questions 💪 The precision oncology potential here for #ccRCC is real 🎯 Watching this program closely 👀 #AACRKidney2026 #KidneyCancer #RCC #HIF2alpha #GUOnc #Casdatifan #Biomarkers

@FaltasLab @Stefani19753108 @Uroweb @AStenzl @MaartenAlbersen @WCMDeptofMed @WCMEnglanderIPM @IBCG_BladderCA @urotoday @ASCOPost @nyphospital @EUplatinum @HemOncToday @ElementoLab @notSoJunkDNA Congrats Bishoy @FaltasLab on receiving the European Association of Urology Prize for Best Paper in Fundamental Research at the #EAU26 in London. Well deserved recognition for outstanding work on the heterogeneity and evolution of urothelial cancer. 👏 #BladderCancer

Exercise matters. Sleep still matters first! Exercise looked more helpful when sleep was sufficient. nature.com/articles/s4159…

Better Together 🧡 Supporting the #KidneyCancer community means supporting each and every patient. This #KidneyCancerAwarenessMonth, we’re proud to highlight our friends at the @tRCCProject. They are accelerating research and discovery for translocation renal cell carcinoma (tRCC), a rare subtype that needs more answers. Because of this rarity, partnership is our greatest tool for progress. The project is building a first-of-its-kind dataset—combining clinical data and genomic sequencing with the most important piece of the puzzle: the patient experience. If you or a loved one have been diagnosed with tRCC, your experience can drive breakthroughs. The project is open to participants diagnosed in the U.S. and Canada. 🔗 Learn more at trccproject.org #tRCCProject #BetterTogether #AcceleratingCures

@UMichRadOnc hosted the inaugural Felix Feng Visiting Professorship to honor the legacy and career of a brilliant scientist and physician. His roots still run very deep and we could not have asked for a better guest speaker than @DrPaulNguyen to pay tribute. @UMRogelCancer

The role of liquid biopsy in the management of patients with genitourinary malignancies. @maughanonc @huntsmancancer joins @UroDocAsh @MDAndersonNews to discuss how liquid biopsy in bladder cancer has rapidly evolved from a research tool into a clinically actionable technology over the past several years. Dr. Maughan outlines current applications—including tracking treatment response, detecting minimal residual disease, and finding actionable genomic alterations—from blood and urine samples as sequencing and genomic analysis have become more sophisticated. #WatchNow to learn more > bit.ly/4tph9oH

Ab#488 @ASCO #GU26 by @gabriel__hooper👉bit.ly/4s2vlT1👉pts w/ mRCC #kidneycancer on belzutifan👉53% had gr≥3 hypoxia; 80% gr≥2 anemia👉data suggest close monitoring of pts on belzutifan living/visiting high altitude areas👇@OncoAlert @urotoday @KidneyCAN

Love that combos are more frequently used in GU cancers—but are they always better than sequential tx? PFS/DFS isn’t always the whole story! Thanks for the conversation @Micah_Ostrowski

Ab#92 @ASCO #GU26 by @varun05n👉bit.ly/4r3FYEw👉End-of-life (EOL) Rx analysis of ~10,000 pts w/ mCRPC #prostatecancer in @flatironhealth👉~60% remained on Rx in last 3 mo of life👉need for more patient-centered EOL care👇@umangtalking @OncoAlert @urotoday @PCF_Science

Great time @RutgersCancer. Thanks for the kind invitation.

Huge congratulations to @drtanws on being awarded the prestigious Hunterian Professorship by Royal College of Surgeons of England. A well-deserved recognition of his outstanding work in defining NMIBC risk stratification in bladder cancer. Proud to see you continue to excel and lead on the global stage! @Yale_Urology @UCLDivofSurgery @MDAndersonNews #OncSurgery @RCSnews @SUO_YUO @UroToday

Lots of interest in the immunotherapy timing trial but this thread highlights a number of interesting findings about the study

Looking back at #IKCSNA25, patient advocate @LauraEsfeller interviewed @OpurumPrecious @UofUHealth about the impact of obesity on kidney cancer. youtube.com/watch?v=edRfV0… Stay tuned for more cutting-edge research at #IKCSEU26!